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Abstract
Purpose Primary mesenchymal tumors of the pancreas are
rare, with leiomyosarcomas the most encountered entities
among the pancreatic sarcomas. With few exceptions, single
case reports published over the last six decades constitute the
entire scientific literature on this topic. Thus, evidence regard-
ing clinical decision-making is scant.
Methods Based on a case report and an extensive literature
search in PubMed, we discuss the clinical aspects and current
management of this rare malignancy.
Results We identified only two papers with more than a single
case presentation; these institutional patient series were limit-
ed to five and nine patients. Additionally, a few papers sought
to summarize the individual case reports published in the
English and/or Chinese language. The clinical presentation
is rather non-specific. Moreover, modern imaging modalities
are insufficiently accurate to diagnose leiomyosarcoma of the
pancreas. Treatment goals include a complete resection with
free margins. Proper morphologic examination using immu-
nohistochemistry and the application of a grading system are
clinically important for prognostication. The efficacy of adju-
vant treatments has not been established.
Conclusion Primary pancreatic leiomyosarcoma is extremely
rare, and the scientific literature is primarily based on single
case reports. Conclusions on management and prognosis
should be drawn with caution. A multidisciplinary team con-
sultation is warranted to discuss a thorough individual treat-
ment plan based on the available scientific literature, despite
its low evidence level.
Keywords Pancreas . Leiomyosarcoma .Mesenchymal
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Introduction
Pancreatic adenocarcinoma is a common and increasingly
prevalent malignancy of the pancreas worldwide [1–3],
representing more than 90–95 % of all pancreatic malignant
tumors. In contrast, primary mesenchymal tumors of the pan-
creas are rare [4–7] with a reported 0.1 % incidence of pan-
creatic sarcoma diagnosed after autopsy involving 5057 cases
of malignant pancreas tumors [8]. Most pancreatic mesenchy-
mal tumors are gastrointestinal stromal tumors (GIST) or neu-
rogenic tumors [4, 6]. Among the pancreatic sarcomas,
leiomyosarcoma is the most encountered entity [9]. Only 69
cases were reported in scientific English (n = 49) and Chinese
(n = 20) medical journals [10] from 1951, when Ross [11]
reported the first case of a primary pancreatic leiomyosarcoma
(PLMS), to 2013. Thus, the clinical presentation and diagnos-
tic characteristics of this rare lesion may be difficult to
anticipate.
In this study, we present a case report and aim to discuss the
clinical aspects and current management of this rare malignant
pancreatic tumor based on a comprehensive review of the
available literature.
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Case Report
A 55-year-old male with a previous history of hepatitis C and
a history of two cardiac infarctions was seen by his general
practitioner in evaluation of epigastric symptoms. A general
work-up that included a negative upper endoscopy was per-
formed. An abdominal computed tomography (CT) per-
formed outside the hospital revealed a lesion within the tail
of the pancreas (Fig. 1), which was also visualized on an
additional magnetic resonance tomography imaging (MRI)
exam (Fig. 2). Because the imaging findings suggested a het-
erogeneously enhanced lesion, a neuroendocrine tumor was a
differential diagnostic consideration.
Based on the imaging findings, the patient was referred to
our department. The general laboratory biochemistry analysis
was within normal limits. Except for a slightly increased se-
rum chromogranin A (CgA) of 6.7 nmol/l (normal, <3.5 nmol/
l ) , o ther tumor markers were normal inc luding
carcinoembryonic antigen (CEA) (2 μg/l; normal, <5 μg/l)
and carbohydrate antigen 19–9 (CA 19–9) (5 kU/l; normal,
<60 kU/l).
Three-phase pancreas CT protocol imaging was per-
formed, showing a 17 × 15-mm solid lesion that was slightly
abutting against the splenic vein in the pancreatic tail (Fig. 3).
Clinical symptoms or signs of metastatic disease or a func-
tional pancreatic neuroendocrine tumor were absent, as were
any imaging findings of metastatic disease.
After a multidisciplinary team consultation (i.e., surgeon,
oncologist, radiologist), primary surgical treatment of the
suspected malignant tumor was recommended.With informed
consent from the patient, an uneventful open distal pancreas
resection with splenectomy was performed. The patient
developed postoperative pneumonia, and eventually a wound
rupture occurred that prompted re-operation on the ninth post-
operative day (POD). He was discharged home on the 13th
POD after the pancreas resection in good condition, and his
subsequent recovery was uneventful.
Macroscopically, a 17-mm homogenous tumor with a sol-
id, slightly whorled cut surface was identified in the distal
pancreas in close proximity to and probably originating from
a venous blood vessel. On the dorsal pancreatic surface of the
specimen, a small inked focus was seen on a part of the tumor
margin. While this tissue area was somewhat traumatized,
which would likely blur the inking, the other assessable sur-
gical margins were tumor free, suggesting a radical resection
(R0).
Microscopy confirmed the close relationship of the tumor
to a venous blood vessel (Fig. 4) and revealed an infiltrating
tumor with spindle cell morphology emanating from the ves-
sel wall. Cellular atypia was evident, and mitoses were easily
identified (Fig. 5). Atypical mitoses were also present (Fig. 6).
Immunohistochemical staining was positive for actin 1A4
(smooth muscle actin), muscle-specific actin (actin HHF35)
(Fig. 4b), and desmin (Fig. 5), supporting smooth muscle
differentiation. No staining for CD117 and CD34 or neuroen-
docrine markers (synaptophysin and chromogranin A) was
evident. The proliferation marker Ki-67 was positive in ap-
proximately 50 % of the tumor cells in Bhot spots^ (i.e., the
strongest positive area of the tumor).
A routine section taken from the spleen was negative for
tumor markers. A total of five benign lymph nodes were
harvested.
The tumor morphology was consis tent with a
leiomyosarcoma of the pancreas originating from an
intrapancreatic venous blood vessel [12]. According to the
French grading system [13, 14], which is a three-grade system
Fig. 1 Abdominal computed tomography (CT) shows a 15 × 12-mm
tumor (white arrow), which is heterogeneously enhanced by contrast
media
Fig. 2 Magnetic resonance imaging (T1 sequence) shows the same
lesion identified by CT as a 17 × 14-mm heterogeneously enhanced
lesion (white arrows) of the pancreatic tail
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mainly based on histologic type and subtype, tumor necrosis,
and mitotic activity, the tumor was grade II (Table 1).
Literature Search
A literature search in PubMed was conducted using terms
inc lud ing Bpanc reas ,^ Bpancrea t i c ,^ Bsa rcoma ,^
Ble iomyosarcoma,^ Bangiole iomyosarcoma,^ and
Bmesenchymal.^
Results
We were unable to identify any scientific publications on this
topic since 2015, whenMilanetto et al. reported another single
case and summarized 44 previous papers published between
1951 [11] and 2014 [6] in the English literature, including
only 2 reports comprising more than a single case (i.e., 5 [8]
and 9 patients [9]). Except these few reports [8, 9], the litera-
ture published over the last six decades on this topic comprises
single case reports only.
Brief Summary of the Literature
Baylor and Berg [8] summarized their experience of 5 cases
identified at autopsy among 5000 deceased patients with pre-
sumptive pancreatic cancer, whereas Zhang et al. [9] reported
on an institutional series of 9 patients diagnosed at the Mayo
Clinic, MN, USA from 1994 to 2006. A review of 35 cases of
pancreatic leiomyosarcoma in the English scientific literature
was reported by Aihara et al. in 2002 [15]. A decade later (in
2013), a systematic review of 69 case reports published in
Chinese and English journals summarized pertinent informa-
tion and described the clinical characteristics and the progno-
sis of this rare entity [10]. This report included a search for
case reports via the China Knowledge Resource Integrated
Database. Furthermore, in 2015, Milanetto et al. [16] summa-
rized the clinical features of 45 cases reported in the English
literature up to that date, which included their own case.
In summary, based on the available literature on this topic
[8–10, 15, 16], the distribution between the sexes is equal, and
the median age is approximately 55 years (almost two decades
younger than for pancreatic ductal adenocarcinoma), ranging
from 15 to 85 years. Clinical symptoms were reported in 90%
of cases, with the presence of an abdominal mass (50 %),
abdominal pain (43 %), and weight loss (33 %), the most
Fig. 3 a CT of the pancreas with intravenous contrast in the arterial phase (red arrows) shows a 17 × 15-mm tumor with heterogeneous contrast
enhancement. b CT of the pancreas in the venous phase shows the tumor (blue arrows) in the pancreatic tail
Fig. 4 a HE ×20 magnification. Lumen of the intrapancreatic venous
vessel with the tumor (T) infiltrating the pancreatic tissue (Pa). b
Positive staining with actin HHF35. White arrows indicate smooth
muscle in the vessel wall. Black arrows indicate the spindle cell
proliferation as positive for muscle-specific actin, which is consistent
with a leiomyosarcoma
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common clinical symptoms encountered in these patients
[10]. Jaundice, anemia, gastrointestinal bleeding, and
vomiting were also reported in a few patients. Whereas seven
of nine tumors were located in the head of the pancreas in the
Mayo Clinic series [9], no differences regarding the tumor
location, i.e., in the head or the body-tail of the pancreas, were
determined from the available literature [10]. At diagnosis, a
median tumor size of 10 cm (range, 1–30 cm) was reported.
Based on the available information on gross morphology,
53 % of the tumors were solid, 16 % were cystic, and 31 %
had a mixed pattern [10].
Zhang et al. reported that four of nine patients had liver
metastases at the time of diagnosis [9]. Based on a review of
68 patients with reported metastatic status [10], distant metas-
tasis was diagnosed in 25% of the patients and 19% had local
invasion into adjacent vessels/organs. In contrast, lymph node
metastasis was confirmed in only one patient (1.5 %) [10].
Information on surgical treatment was available for 62 pa-
tients: 65 % underwent radical surgery, whereas the remaining
patients had a palliative procedure or a biopsy only. Long-
term follow up data were available for survival analysis in
49 (71 %) of the 69 cases [10]. The overall 1-, 3-, 5-, and
10-year survival rates were 66.6, 51.2, 43.9, and 29.3 %, re-
spectively [10]. Multivariate analysis showed that a non-
radical resection was a significant adverse prognostic factor
and that adjacent organ/vessel invasion might also be a detri-
mental factor for long-term survival [10]. In the Mayo Clinic
series [9], a median survival of 13 (range, 5–98) months was
achieved in the nine patients, of whom four were surgically
treated with a pancreatoduodenectomy, three had a palliative
procedure, and two underwent biopsy only but endured a det-
rimental outcome when a resection could not be employed.
Surgical resection with free margins was suggested as the
only possible curative treatment by the authors, and a role for
adjuvant therapies has remained undetermined [9, 10, 17].
Discussion
Solid pancreatic tumors require a standard work-up including
proper imaging [18, 19]. Initial suspicions favor ductal adeno-
carcinoma or less frequently, pancreatic neuroendocrine tumor
[19–22]. In patients with a history of a malignancy, metastases
to the pancreas from another primary site should also be con-
sidered [19, 23–25].
Pancreatic origin was likely in the present case, with a
small tumor clearly confined to the pancreatic gland [26].
Fig. 6 a Discernibly atypical
sarcoma cells (black arrows),
some of which are pleomorphic
and show abnormal nuclei,
infiltrating the pancreatic soft
tissue (magnification ×200). b
Normal acinar pancreatic
parenchyma (red arrows) with
atypical sarcoma cells infiltrating
the pancreatic tissue (black
arrows) (magnification ×400)
Fig. 5 Discernibly atypical tumor cells (white arrows) with positive
staining for desmin, a relatively specific marker for muscle
differentiation (magnification ×600)
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Moreover, metastatic leiomyosarcoma isolated to the pancreas
from a distant primary tumor site is extremely rare [27].
The rare entity of primary pancreatic leiomyosarcoma
may be diagnosed exclusively based on histopathologic
morphology [28]. The term leiomyosarcoma includes a
spectrum of diseases ranging from low-grade cutaneous
lesions with a relatively indolent behavior to aggressive
deep lesions of the abdomen or extremities with significant
metastatic potential. Distinguishing a leiomyosarcoma
from the most commonly encountered mesenchymal gas-
trointestinal tumor (i.e., the gastrointestinal stromal tumor,
GIST [29], characterized by the presence of activating mu-
tations in KIT or PDGFRA, and expression of CD 117 and/
or CD34) is highly important. Characteristically, a
leiomyosarcoma shows positive staining for smooth mus-
cle actin and desmin, as also demonstrated in the present
case, and may be properly diagnosed when relevant immu-
nohistochemistry (IHC) is employed. The advent of molec-
ular pathology and expanded immunohistochemical stain-
ing options have conferred greater accuracy to this diagno-
sis [28, 30]. Histologic grading [14] is generally an impor-
tant prognostic factor and also an indicator of metastatic
risk in adult soft tissue sarcomas [13]. The French [14] and
the National Cancer Institute [31, 32] grading systems are
the most commonly used, both of which are three-grade
systems. Grading should be included routinely in the path-
ologic report [13].
Thus, while the rarity of pancreatic mesenchymal tumors is
evident, misclassification between subclasses of other rather
uncommon mesenchymal tumors may partly explain the ex-
treme scarcity of primary pancreatic leiomyosarcomas reported
in the literature.Moreover, the exact topographic localization of
the reported leiomyosarcomas has not always been provided,
which may also obscure the exact organ distribution [33].
As observed in the present case, the clinical signs and symp-
toms in this group of patients are non-specific [10]. In the
absence of overt clinical manifestations, small pancreatic tu-
mors are typically identified incidentally. Arriving at an accu-
rate diagnosis based on imaging alone may be challenging [18,
19, 34]. This dilemma particularly obtains for the rare pancre-
atic tumors (i.e., solid pseudopapillary tumor (SPT), pancreatic
lymphoma, pancreatoblastoma, andmetastasis to the pancreas).
Alternatively, Srivastava et al. [35], based on the CT findings of
four patients, proposed that pancreatic leiomyosarcoma should
be entertained when all the findings of large size at presenta-
tion, increased vascular enhancement, and the absence of bili-
ary dilatation are present. A similar conclusion regarding a
large heterogeneous mass containing necrotic and calcified
areas has been reported by other investigators [36, 37]. As
described by Machado et al. [37], an 18F-fluorodeoxygliose
positron emission tomography (FDG-PET) scan revealed an
area of increased tumor metabolic activity and a central area
of low metabolic activity, which supported suspicions of a ma-
lignant mesenchymal tumor. Others have reported on contrast
enhancements in both the arterial and venous phases [38].
According to Paciorek and Ross [39], tumor localization using
MRI was best achieved through the unenhanced T1- and T2-
weighted images. Consistent with the observed MRI character-
istics of leiomyosarcomas occurring in other organs, most pan-
creatic lesions were isointense with skeletal muscle on T1-
weighted images and hyperintense on T2-weighted images.
Furthermore, gadolinium enhancement was usually heteroge-
neous. Pancreatic leiomyosarcomas had characteristics similar
to typical pancreatic adenocarcinomas; however, diffusion-
weighted imaging techniques contributed only marginally to
the diagnosis, detection, and characterization of a focal pancre-
atic lesion. This study concluded that differentiation from the
far more commonly occurring adenocarcinoma was not
Table 1 Criteria definitions and
grading system for soft-tissue
sarcomas according to Bthe
French system^ (Fédération
Nationale des Centers de Lutte de
Cancer, FNCLCC) (after Trojani
et al. [14])
Criterion Score Definition
Tumor differentiation 1 Well-differentiated tumors
2 Sarcomas with specific histologic typing
3 Embryonal, undifferentiated, or sarcomas
of uncertain tumor type
Mitosis count (counted at ×400 magnification
in ten consecutive fields)
1 0 to 9 mitoses per 10 HPFa
2 10 to 19 mitoses per 10 HPF
3 More than 20 mitoses per 10 HPF
Tumor necrosis 0 No necrosis on any examined slides
1 <50 % tumor necrosis
2 ≥50 % tumor necrosis
Histologic grade
Grade I Total score 2–3
Grade II Total score 4–5
Grade III Total score 6–8
aA high-power field (HPF) is equal to 0.1734 mm2
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possible [39]. Conversely, as observed in pancreatic metastases
from primary leiomyosarcomas located elsewhere, CT imaging
displays a hypovascular pattern in the arterial phase, with ho-
mogeneous enhancement in the venous phase in half of the
patients [40]; thus, multidetector CT angiography is regarded
as a highly accurate technique for characterizing pancreatic
metastases [41, 42].
While the tool box for pancreas imaging is continuously
expanding and improving [18], still a number of common and
uncommon pitfalls can be encountered [43]. By the clinical in-
troduction of high-resolution endoscopic ultrasound (EUS), a
new imaging approach became available. In addition to describ-
ing various patterns of the pancreatic gland, pathology related to
its ductal structures or vessels, and any diagnosed lesions could
be reported by this novel approach. Moreover, EUS enables a
more imaging-directed biopsy of lesions, and also a novel path to
procure core tissue for molecular analysis [44]. Thus, its use has
gained broad acceptance in recent years, and has been part of the
diagnostic and staging tools, both for solid and cystic primary
pancreas tumors [45–47], but also for suspected metastasis to the
gland [23]. Of note, EUS is operator-dependent, and specialized
training in both endoscopy and ultrasound is required. High-
quality EUS was not available at our institution at the time of
diagnostic work-up for our patient. If available at that time, EUS
with imaging-directed biopsy could have provided information of
clinical relevance. In this particular case, with a rather small re-
sectable pancreatic tumor, most likely the surgical treatment and
timing, and the procedure employed would have been the same.
In retrospect, our interpretation of the peripheral contrast
enhancement of the tumor together with a slightly elevated
CgA as suggestive of a neuroendocrine tumor was incorrect.
However, a neuroendocrine tumor (NET) or a neuroendocrine
carcinoma (NEC) may be more common in the pancreas than
a primary leiomyosarcoma, and a clear distinction between
these entities may prove difficult without well-defined char-
acteristics identified for each entity.
Surgery with free tumor margins is standard treatment for
localized sarcomas [18]. Due to the tumor size encountered at
the time of diagnosis, this procedure may include a major radical
or perhaps a multivisceral resection in many patients. However,
when the pancreatic tumor is small, as in the present case, limiting
the extent of surgery to achieve free margins appears appropriate
[15]. Indications for adjuvant treatments with radiation and/or
chemotherapy in the setting of abdominal sarcomas are not well
described, and no consensus exists regarding the clinical effects
of these modalities. Currently, doxorubicin-based chemotherapy
is suggested as first-line treatment in adults with leiomyosarcoma
not amenable to curative-intent surgery [48], whereas 6 cycles of
doxycycline and ifosfamide have been reported as an option in
the adjuvant setting [49]. Moreover, gemcitabine-based chemo-
therapy has been evaluated, though inconclusively [50].
Recently, more attention has been directed toward the under-
lying biology of individual sarcoma subtypes. Additionally,
greater specificity has been applied to the selection of chemother-
apeutic agents based on their activity against the individual histo-
logical subtypes [51]. Despite these advances, themanagement of
sarcomas, particularly concerning rare subtypes, remains a major
challenge. With the paucity of available clinically effective treat-
ments for patients with advanced or metastatic leiomyosarcoma,
the recently entertained novel therapeutic targets may auger hope
for the development of alternative therapeutic strategies [52].
The extremely rare occurrence of primary pancreatic
leiomyosarcoma and a scientific literature primarily based on
single cases present challenges in establishing any firm conclu-
sions onmanagement and prognosis. In patients with a pancreatic
tumor, proper imaging should be employed to arrive at the most
likely pre-operative diagnosis and to stage the disease properly.
Moreover, radical surgery with free margins should be the aim
when possible, and the proper use of relevant IHC should enable
an accurate diagnosis. Whether molecular parameters may con-
tribute to the tumor grading and prognostication remains undeter-
mined [13]. In cases of primary pancreatic leiomyosarcoma, mul-
tidisciplinary team consultation is warranted, although the evi-
dence for any decision-making rests on a rather sparse literature.
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